FDA Clears Protego's PROT-001 for Phase 2/3 Trial in AL Amyloidosis
The U.S. Food and Drug Administration has cleared the Investigational New Drug application for PROT-001, Protego Biopharma said. The clearance lets the company start SHIELD-AL, a global pivotal Phase 2/3 study in newly diagnosed lambda AL amyloidosis patients.
- The FDA cleared Protego Biopharma's IND for PROT-001, an oral investigational lambda light chain stabilizer.
- The clearance enables SHIELD-AL, a global randomized, double-blind, placebo-controlled Phase 2/3 study in newly diagnosed lambda AL amyloidosis.
- PROT-001 will be tested as an add-on to standard-of-care plasma cell-directed therapy.
- Part A covers safety and dose confirmation, and Part B is the pivotal safety and efficacy study.
- Phase 1 data in healthy volunteers are to be presented at a medical meeting later this year.
What the clearance allows
Protego Biopharma, a clinical-stage biotechnology company based in San Diego that develops small molecule therapies for protein misfolding diseases, announced the IND clearance on Oct. 19, 2026. According to the company, PROT-001 is an oral, investigational, first-in-class lambda light chain stabilizer for AL amyloidosis.
The drug will be tested as an add-on to standard-of-care plasma cell-directed therapy. Those standard treatments work by reducing the production of light chain proteins, while PROT-001 is meant to act on the proteins themselves.
Design of the SHIELD-AL study
SHIELD-AL is a randomized, double-blind, placebo-controlled study in newly diagnosed lambda AL amyloidosis patients. It has two parts:
- Part A: an initial safety and dose confirmation study.
- Part B: a pivotal safety and efficacy study.
Protego also said it will share data from its completed Phase 1 study of PROT-001 in healthy volunteers at a medical meeting later this year. The release gives no further detail on those results.
The rationale: stabilizing toxic light chains
In AL amyloidosis, abnormal plasma cells produce light chain proteins that can misfold and aggregate. Protego describes the disease as rare and life-threatening, affecting over 5,100 newly diagnosed patients annually and 28,000 US adults. The toxic light chains and their buildup as amyloid deposits injure organs, including the heart and kidneys. Cardiac damage is especially serious, according to the company, because light chains can directly impair cardiomyocyte function while deposits disrupt the heart's structure and function.
Protego describes PROT-001 as a small molecule pharmacological chaperone designed to stabilize amyloidogenic lambda light chain proteins and prevent misfolding and the formation of proteotoxic species. By targeting the protein before it adopts a pathogenic conformation, the company says, the drug has the potential to complement existing treatments and address an additional mechanism of disease.
Chief Executive Officer Brent J. Warner said that studies in newly diagnosed patients with cardiac involvement have shown that "rapid depletion of amyloidogenic light chains closely correlates to improvements in survival." He added that SHIELD-AL "will evaluate whether this complementary approach with PROT-001 can help patients achieve deeper and faster organ responses while reducing cardiovascular complications beyond standard of care alone."
What it means for patients and the field
The clearance is a regulatory step that permits the trial to begin, not evidence that PROT-001 works. No efficacy data for the drug in patients have been reported. The study will test whether adding a light chain stabilizer to existing therapy improves organ outcomes.
Protego notes that current treatments focus on reducing light chain production and managing organ complications, leaving patients with a substantial need for complementary approaches that directly address light chain toxicity. If SHIELD-AL succeeds, it would be tested in exactly that gap, but the release provides no timelines for enrollment or results.
